Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter
Late-Stage Asset Attracts ‘Robust’ Investors
The company’s fresh cash will fund readouts for lead drug candidate ABC008 from a pivotal Phase II/III trial in inclusion body myositis and from Phase I/II studies in two other rare indications.
